The article presents the results of a clinical study examination the effi cacy and tolerability of the use of fi xed phytocomposition Memostim (Ananta Medicare, United Kingdom) in patients with dyscirculatory encephalopathy (DE) stage II, caused by metabolic syndrome.

The phytocomposition was given to the Substitutes in 30 patients with DE stage II with metabolic syndrome (main study group) within 3 months. Patients received 1 capsule 2 times a day during the fi rst month, then 1 capsule 1 time per day for two months. The comparison group consisted of 30 patients with DE stage II with a metabolic syndrome, where phytocomposition Memostim was not add to the standard course of therapy.

Effi ciency and safety of phytocomposition of the Memostim were assessed on the basis of clinical neurological, psychodiagnostical, biochemical, immunoenzymatic, and statistical methods.

After three months of treatment, a signifi cant decrease in the frequency and intensity of clinical and neurological manifestations of the disease was observed, and a positive dynamics in the neurocognitive sphere, psycho-emotional state of patients was noted. The concentration of the human nerve growth factor (NGF-β) increased for 67 %, which indicated the recovery of neuroplasticity.